drugset
drugset / Trial / NCT05628103

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

NCT05628103 ↗

Phase 3 Completed 101 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.

Timeline

Start
2022-12-19
Primary completion
2024-04-01
Completion
2024-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulotaront Small molecule 50 mg Oral
Subject Ulotaront Small molecule 75 mg Oral
Subject Ulotaront Small molecule 100 mg Oral

Indications

schizophrenia